

Miqueias Lopes-Pacheco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5958336/publications.pdf>

Version: 2024-02-01

48
papers

1,907
citations

257101

24
h-index

264894

42
g-index

48
all docs

48
docs citations

48
times ranked

2258
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 181-187.	0.3	17
2	Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A. <i>Cells</i> , 2022, 11, 136.	1.8	11
3	CFTR interactome mapping using the mammalian membrane two-hybrid high-throughput screening system. <i>Molecular Systems Biology</i> , 2022, 18, e10629.	3.2	13
4	Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 857573.	2.2	70
5	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
6	Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 600711.	1.8	51
7	Oxidative Stress-Derived Mitochondrial Dysfunction in Chronic Obstructive Pulmonary Disease: A Concise Review. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-11.	1.9	7
8	Discovery of CFTR modulators for the treatment of cystic fibrosis. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 897-913.	2.5	38
9	Mitochondria-Rich Fraction Isolated From Mesenchymal Stromal Cells Reduces Lung and Distal Organ Injury in Experimental Sepsis*. <i>Critical Care Medicine</i> , 2021, 49, e880-e890.	0.4	15
10	Mesenchymal Stromal Cells From Emphysematous Donors and Their Extracellular Vesicles Are Unable to Reverse Cardiorespiratory Dysfunction in Experimental Severe Emphysema. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 661385.	1.8	14
11	Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 693-723.	1.5	24
12	Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 425.	2.4	15
13	Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. <i>Cell Biology and Toxicology</i> , 2020, 36, 83-102.	2.4	56
14	Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma. <i>Stem Cells Translational Medicine</i> , 2020, 9, 250-260.	1.6	34
15	Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma. <i>Stem Cell Research and Therapy</i> , 2020, 11, 167.	2.4	14
16	Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. <i>Biochemical Pharmacology</i> , 2020, 180, 114133.	2.0	14
17	Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis. <i>Stem Cell Research and Therapy</i> , 2019, 10, 264.	2.4	33
18	Mesenchymal Stromal Cells Are More Effective Than Their Extracellular Vesicles at Reducing Lung Injury Regardless of Acute Respiratory Distress Syndrome Etiology. <i>Stem Cells International</i> , 2019, 2019, 1-15.	1.2	47

#	ARTICLE	IF	CITATIONS
19	Current understanding of the immunosuppressive properties of mesenchymal stromal cells. <i>Journal of Molecular Medicine</i> , 2019, 97, 605-618.	1.7	81
20	Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1440.	1.6	6
21	Serum from Asthmatic Mice Potentiates the Therapeutic Effects of Mesenchymal Stromal Cells in Experimental Allergic Asthma. <i>Stem Cells Translational Medicine</i> , 2019, 8, 301-312.	1.6	40
22	Increases in cytosolic Ca ²⁺ induce dynamin- and calcineurin-dependent internalisation of CFTR. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 977-994.	2.4	13
23	CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. <i>Frontiers in Pharmacology</i> , 2019, 10, 1662.	1.6	287
24	Effects of mesenchymal stromal cells play a role the oxidant/antioxidant balance in a murine model of asthma. <i>Allergologia Et Immunopathologia</i> , 2018, 46, 136-143.	1.0	22
25	Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome*. <i>Critical Care Medicine</i> , 2018, 46, e132-e140.	0.4	59
26	Impact of one versus two doses of mesenchymal stromal cells on lung and cardiovascular repair in experimental emphysema. <i>Stem Cell Research and Therapy</i> , 2018, 9, 296.	2.4	22
27	Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells. <i>Experimental Cell Research</i> , 2018, 372, 99-107.	1.2	5
28	Impact of different intratracheal flows during lung decellularization on extracellular matrix composition and mechanics. <i>Regenerative Medicine</i> , 2018, 13, 519-530.	0.8	5
29	Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma. <i>Frontiers in Immunology</i> , 2018, 9, 1147.	2.2	36
30	Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 2194-2210.	1.1	41
31	Therapeutic effects of bone marrow-derived mononuclear cells from healthy or silicotic donors on recipient silicosis mice. <i>Stem Cell Research and Therapy</i> , 2017, 8, 259.	2.4	14
32	Cell-Based Therapy for Silicosis. <i>Stem Cells International</i> , 2016, 2016, 1-9.	1.2	73
33	Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis. <i>PLoS ONE</i> , 2016, 11, e0147005.	1.1	58
34	CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2016, 7, 275.	1.6	115
35	Association with Amino Acids Does Not Enhance Efficacy of Polymerized Liposomes As a System for Lung Gene Delivery. <i>Frontiers in Physiology</i> , 2016, 7, 151.	1.3	3
36	Moderate Aerobic Training Improves Cardiorespiratory Parameters in Elastase-Induced Emphysema. <i>Frontiers in Physiology</i> , 2016, 7, 329.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis. <i>ChemBioChem</i> , 2016, 17, 493-505.	1.3	26
38	Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation. <i>PLoS ONE</i> , 2015, 10, e0119796.	1.1	40
39	Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema. <i>Frontiers in Physiology</i> , 2015, 6, 267.	1.3	18
40	Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 19743-19755.	1.6	41
41	Combination of Correctors Rescue Δ F508-CFTR by Reducing Its Association with Hsp40 and Hsp27. <i>Journal of Biological Chemistry</i> , 2015, 290, 25636-25645.	1.6	40
42	Pilot safety study of intrabronchial instillation of bone marrow-derived mononuclear cells in patients with silicosis. <i>BMC Pulmonary Medicine</i> , 2015, 15, 66.	0.8	28
43	Effects of bone-marrow derived mononuclear cells from silicotic and healthy donors in experimental silicosis. , 2015, , .		0
44	Infusion of Bone Marrow Mononuclear Cells Reduces Lung Fibrosis but Not Inflammation in the Late Stages of Murine Silicosis. <i>PLoS ONE</i> , 2014, 9, e109982.	1.1	24
45	Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. <i>Respiratory Research</i> , 2014, 15, 118.	1.4	141
46	Single Tyrosine Mutation in AAV8 Vector Capsid Enhances Gene Lung Delivery and Does Not Alter Lung Morphofunction in Mice. <i>Cellular Physiology and Biochemistry</i> , 2014, 34, 681-690.	1.1	11
47	Effects of Bone Marrow-Derived Mononuclear Cells From Healthy or Acute Respiratory Distress Syndrome Donors on Recipient Lung-Injured Mice. <i>Critical Care Medicine</i> , 2014, 42, e510-e524.	0.4	24
48	Repeated Administration of Bone Marrow-Derived Cells Prevents Disease Progression in Experimental Silicosis. <i>Cellular Physiology and Biochemistry</i> , 2013, 32, 1681-1694.	1.1	36